|
OSTPDL1: A phase II study of avelumab, a monoclonal antibody targeting programmed death-ligand 1 (PD-L1) in adolescent and young adult patients with recurrent or progressive osteosarcoma. |
|
|
Research Funding - Pfizer |
|
|
Stock and Other Ownership Interests - GE Healthcare (I) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer (Inst); Lilly (Inst) |
|
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); Lilly (Inst); Loxo (Inst); Salarius Pharmaceuticals (Inst) |
Travel, Accommodations, Expenses - AstraZeneca/MedImmune (Inst); Bayer (Inst); Lilly (Inst); Salarius Pharmaceuticals; Thermo Fisher Scientific |
|
|
Honoraria - Illumina; PACT Pharma |
Consulting or Advisory Role - CytoAgents |
Patents, Royalties, Other Intellectual Property - St. Jude Children's Research Hospital |
Travel, Accommodations, Expenses - 10x Genomics; Aduro Biotech |
|
|
|
|
Patents, Royalties, Other Intellectual Property - St. Jude Children's Research Hospital (Inst) |
Travel, Accommodations, Expenses - Merck |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Amgen |
Honoraria - Eastern Pulmonary Conference (I); France Foundation (I) |
Consulting or Advisory Role - Astellas Pharma; Boehringer Ingelheim (I); Lilly |
Speakers' Bureau - France Foundation (I); Genentech/Roche (I) |
Travel, Accommodations, Expenses - InterMune (I); Takeda |
|
|
|
Consulting or Advisory Role - EUSA Pharma; Loxo/Bayer; Merck |